Most peptides sold online in Australia sit in a grey zone: legal to possess for research, prescription-only for human use, and explicitly banned in sport. Here's what the TGA actually says, how that maps to what people are doing in practice, and what changes the moment you put a peptide into your body instead of a test tube.
Almost every research peptide is a Schedule 4 prescription medicine in Australia. That means a doctor's script is required for human use. Selling, supplying, or administering Schedule 4 substances without authorisation is an offence under each state's Poisons Act. Possession for genuine in-vitro research is generally not prosecuted, which is why "research use only" vials are widely available, but the moment a peptide is intended for injection into a person, the legal framing changes completely.
The Therapeutic Goods Administration (TGA) controls which substances can be supplied as medicines in Australia. Peptides like semaglutide, tirzepatide, BPC-157, ipamorelin, CJC-1295, retatrutide, PT-141 and melanotan II are all Schedule 4, "Prescription Only Medicine", under the Poisons Standard. A small set (e.g. some growth-hormone-releasing peptides) sit in Schedule 9 (prohibited substances) when supplied for non-medical use.
The TGA's Personal Importation Scheme lets an individual import up to a 3-month supply of a Schedule 4 medicine for their own treatment, provided they have a prescription and the substance isn't on the prohibited import list. That carve-out is what most personal compounded peptide shipments rely on.
Sport Integrity Australia and WADA prohibit virtually every research peptide in competition (and most out of competition). If you compete in any sanctioned sport, including masters and amateur leagues, assume any peptide you inject will return an Adverse Analytical Finding. The SIA prohibited list is the authoritative reference.
RUO-labelled peptides are sold for in-vitro experimental use. The label is not a free pass: putting an RUO substance into a human is, in legal terms, supplying an unapproved medicine. Vendors rely on the RUO disclaimer as their own legal cover; it does not extend to the end user.
Independent third-party testing matters more in this grey zone, not less. A vial without a verified Certificate of Analysis is unidentified material. You don't know the identity, the purity, the peptide content, or whether endotoxin levels would clear a bioassay.
The compliant route for human use in Australia is a script from an authorised prescriber, dispensed by a registered compounding pharmacy. Compounded GLP-1s (semaglutide, tirzepatide) and BPC-157 are increasingly available this way. Cost is higher than RUO vials, but you get pharmaceutical-grade sterility, accurate dosing, and a clear chain of custody.
LabDoc is not a pharmacy and doesn't sell peptides. We test the vials you send us and publish independent HPLC purity and LC-MS identity results so anyone, researcher, patient or prescriber, can verify what's actually in a batch before it gets used. Every result is tied to a batch number and laboratory signature; browse the live AU result feed to see what passes and fails in this market.